Similar articles

• Preface: A physical sciences perspective of the evolution of drug resistance in cancer.

  Kuhn NZ, Nagahara L. Kuhn NZ, et al. Mol Pharm. 2011 Dec 5;8(6):1994-5. doi: 10.1021/mp200529w. Mol Pharm. 2011. PMID: 22136314 No abstract available.
• Preface: National Cancer Act.

  Smalley KS. Smalley KS. Adv Pharmacol. 2012;65:xi-xiii. doi: 10.1016/B978-0-12-397927-8.03001-3. Adv Pharmacol. 2012. PMID: 22959037 No abstract available.
• Three known unknowns.

  Bourzac K. Bourzac K. Sci Am. 2014 Jul;311(1):S23-5. Sci Am. 2014. PMID: 24974707 No abstract available.
• Introduction to resistance to anticancer agents.

  Kruh GD. Kruh GD. Oncogene. 2003 Oct 20;22(47):7262-4. doi: 10.1038/sj.onc.1206932. Oncogene. 2003. PMID: 14576836 Review. No abstract available.
• [Epithelial-mesenchymal transition and cancer stem cells].

  Zou DD, Tang XB. Zou DD, et al. Zhonghua Bing Li Xue Za Zhi. 2013 Jan;42(1):62-5. doi: 10.3760/cma.j.issn.0529-5807.2013.01.018. Zhonghua Bing Li Xue Za Zhi. 2013. PMID: 23611281 Review. Chinese. No abstract available.